Inari Medical to Announce Third Quarter 2020 Financial Results

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) will release its third quarter 2020 financial results on November 12, 2020, after market close. A conference call will take place the same day at 1:30 p.m. PT to discuss the results and recent developments. Inari specializes in developing minimally-invasive products for treating venous diseases, with its ClotTriever and FlowTriever systems FDA-approved for deep vein thrombosis and pulmonary embolism respectively.

IRVINE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020. On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID: 6551049. The live webinar of the call may also be accessed by visiting the Events section of Inari's website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari's website.

About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

When will Inari Medical release its financial results for Q3 2020?

Inari Medical will release its financial results for Q3 2020 on November 12, 2020, after market close.

What time is the conference call for Inari Medical's Q3 2020 financial results?

The conference call for Inari Medical's Q3 2020 financial results is scheduled for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on November 12, 2020.

How can I access the conference call for Inari Medical's financial results?

You can access the conference call by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID: 6551049.

What products does Inari Medical focus on?

Inari Medical develops minimally-invasive catheter-based devices to treat venous diseases, specifically targeting deep vein thrombosis and pulmonary embolism.

Are Inari Medical's products FDA-approved?

Yes, Inari Medical's ClotTriever and FlowTriever systems are FDA-approved for treating deep vein thrombosis and pulmonary embolism, respectively.